GlassScriptPhysician profile
John Jude Pacella
NPI 1972530517
$2,997.80
in general payments reported to CMS, 2019-2025
23 companies · $1,001 in 2025
The $1,001 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $559 · 2020: $222 · 2021: $92.41 · 2022: $340 · 2023: $315 · 2024: $469 · 2025: $1,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,784.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recor Medical INC | $397.20 | 2025 | Paradise Ultrasound Renal Denervation System |
| Amgen INC. | $359.50 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $354.44 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $316.66 | 2019-2025 | Jardiance |
| Abbott Laboratories | $238.07 | 2020-2025 | Triclip, Mitraclip, Ultreon |
| Novartis Pharmaceuticals Corporation | $194.36 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $187.20 | 2022-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $161.45 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $136.09 | 2019-2024 | |
| Abiomed | $119.01 | 2024-2025 | Impella |
| Astellas Pharma US INC | $99.95 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $94.53 | 2019 | |
| Sanofi-Aventis U.S. LLC | $86.90 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $66.15 | 2019-2023 | Farxiga |
| Boston Scientific Corporation | $45.85 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $39.20 | 2023 | Optimizer |
| Novo Nordisk INC | $27.06 | 2025 | Wegovy |
| Teleflex LLC | $23.28 | 2023 | Spectre |
| Kiniksa Pharmaceuticals, LTD. | $14.23 | 2023 | Arcalyst |
| Portola Pharmaceuticals, LLC | $14.05 | 2020 | |
| Amarin Pharma, INC. | $11.53 | 2019 | |
| Cardiva Medical, INC. | $11.09 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Pacella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.